MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
91.87
-1.92
-2.05%
After Hours: 91.99 +0.12 +0.13% 16:29 01/22 EST
OPEN
93.79
PREV CLOSE
93.79
HIGH
94.32
LOW
90.24
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
94.90
52 WEEK LOW
13.22
MARKET CAP
6.35B
P/E (TTM)
-25.1823
1D
5D
1M
3M
1Y
5Y
1D
Structure Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 8h ago
Structure Therapeutics Price Target Raised to $105.00/Share From $65.00 by JP Morgan
Dow Jones · 8h ago
JP Morgan Maintains Overweight on Structure Therapeutics, Raises Price Target to $105
Benzinga · 8h ago
Structure Therapeutics price target raised to $105 from $65 at JPMorgan
TipRanks · 13h ago
STRUCTURE THERAPEUTICS INC <GPCR.O>: JP MORGAN RAISES TARGET PRICE TO $105 FROM $65
Reuters · 20h ago
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Goldman Sachs
TipRanks · 2d ago
Structure Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 2d ago
Structure Therapeutics Price Target Raised to $140.00/Share From $90.00 by Guggenheim
Dow Jones · 2d ago
More
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.